NBIX

SEC source: 0001209191-22-006582 · doc4.xml · derivative · entry 1

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,411

Underlying: Common Stock · 75,411 shares

Expires 2032-01-31

F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

SEC source: 0001209191-22-006580 · doc4.xml · derivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,565

Underlying: Common Stock · 20,565 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.

F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.

SEC source: 0001209191-22-006580 · doc4.xml · derivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,049

Underlying: Common Stock · 140,049 shares

Expires 2032-01-31

F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

SEC source: 0001209191-22-005109 · doc4.xml · derivative · entry 3

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2022-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted May 23, 2012 and vested monthly over one year.

SEC source: 0001209191-22-005109 · doc4.xml · nonDerivative · entry 2

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,055

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $73.21 to $75.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-22-005109 · doc4.xml · nonDerivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-003104 · doc4.xml · nonDerivative · entry 1

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,279

F1 · kind: Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 10, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F1 · shares: Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 10, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $72.14 to $76.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: Includes an aggregate of 218 shares purchased on February 26, 2021 and August 31, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0001209191-22-002529 · doc4.xml · derivative · entry 3

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,266 shares

Expires 2022-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted January 12, 2012 and vested monthly over four years.

SEC source: 0001209191-22-002529 · doc4.xml · nonDerivative · entry 2

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,984

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $83.11 to $87.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: Includes an aggregate of 216 shares purchased on February 26, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0001209191-22-002529 · doc4.xml · nonDerivative · entry 1

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-070071 · doc4.xml · nonDerivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,055

F1 · shares: This transaction represents gift/charitable donations effective December 14, 2021. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

SEC source: 0001209191-21-069625 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,448

F1 · balance_after: Includes an aggregate of 207 shares purchased on February 26, 2021 and August 31, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0001209191-21-067870 · doc4.xml · nonDerivative · entry 1

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,349

F1 · kind: Sale of 1,645 shares of common stock issued upon vesting of 3,125 restricted stock units on December 1, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,480) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.45 to $85.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-21-067375 · doc4.xml · derivative · entry 2

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,702

Underlying: Common Stock · 17,702 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of November 29, 2022, November 29, 2023, November 29, 2024, and November 29, 2025.

F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of November 29, 2022, November 29, 2023, November 29, 2024, and November 29, 2025.

SEC source: 0001209191-21-067375 · doc4.xml · derivative · entry 1

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,169

Underlying: Common Stock · 120,169 shares

Expires 2031-11-29

F1 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.

SEC source: 0001209191-21-060283 · doc4.xml · nonDerivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,697

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.23. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.

SEC source: 0001209191-21-060281 · doc4.xml · derivative · entry 4

Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,400

Underlying: Common Stock · 5,000 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years.

SEC source: 0001209191-21-060281 · doc4.xml · nonDerivative · entry 3

Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,273

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.75 to $105.085. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-21-060281 · doc4.xml · nonDerivative · entry 2

Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,273

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-060281 · doc4.xml · nonDerivative · entry 1

Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,273

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.75 to $104.755. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-21-059839 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,841

F1 · kind: Sale of 987 shares of common stock issued upon vesting of 1,875 restricted stock units on October 4, 2021 to cover payroll and withholding taxes, with the balance of the shares (888) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · balance_after: Includes 216 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 26, 2021.

SEC source: 0001209191-21-052337 · doc4.xml · nonDerivative · entry 1

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,608

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · balance_after: Includes 137 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 26, 2021.

SEC source: 0001209191-21-048560 · doc4.xml · nonDerivative · entry 1

Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,801

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $93.13 to $95.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-21-040445 · doc4.xml · nonDerivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,697

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.04 to $100.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.

SEC source: 0001209191-21-034395 · doc4.xml · derivative · entry 1

Sharp Shalini · CIK 0001377202 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,833

Underlying: Common Stock · 8,833 shares

Expires 2031-05-19

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021.

SEC source: 0001209191-21-034392 · doc4.xml · derivative · entry 1

RASTETTER WILLIAM H · CIK 0001205903 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,833

Underlying: Common Stock · 8,833 shares

Expires 2031-05-19

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021.

SEC source: 0001209191-21-034389 · doc4.xml · derivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,833

Underlying: Common Stock · 8,833 shares

Expires 2031-05-19

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021.

SEC source: 0001209191-21-034386 · doc4.xml · derivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,833

Underlying: Common Stock · 8,833 shares

Expires 2031-05-19

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021.

SEC source: 0001209191-21-034383 · doc4.xml · derivative · entry 1

Norwalk Leslie V · CIK 0001533568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,833

Underlying: Common Stock · 8,833 shares

Expires 2031-05-19

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021.

SEC source: 0001209191-21-034380 · doc4.xml · derivative · entry 1

MORROW GEORGE J · CIK 0001068754 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,833

Underlying: Common Stock · 8,833 shares

Expires 2031-05-19

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021.

SEC source: 0001209191-21-034378 · doc4.xml · derivative · entry 1

Mercier Johanna · CIK 0001782135 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,833

Underlying: Common Stock · 8,833 shares

Expires 2031-05-19

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021.

SEC source: 0001209191-21-034376 · doc4.xml · derivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,833

Underlying: Common Stock · 8,833 shares

Expires 2031-05-19

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021.

SEC source: 0001209191-21-026942 · doc4.xml · derivative · entry 1

Mercier Johanna · CIK 0001782135 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,180

Underlying: Common Stock · 17,180 shares

Expires 2031-04-15

F1 · derivative.exercise_date: Option granted April 15, 2021 and vests in 36 equal monthly installments.

SEC source: 0001209191-21-010498 · doc4.xml · derivative · entry 5

Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,533

Underlying: Common Stock · 1,700 shares

Expires 2026-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted February 05, 2016 and vested monthly over four years.

SEC source: 0001209191-21-010498 · doc4.xml · nonDerivative · entry 4

Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,510

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.95 to $119.9650. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-21-010498 · doc4.xml · nonDerivative · entry 3

Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,110

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-010498 · doc4.xml · nonDerivative · entry 2

Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,510

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.95 to $119.97. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-21-010498 · doc4.xml · nonDerivative · entry 1

Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,610

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-009115 · doc4.xml · derivative · entry 13

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 36,194 shares

Expires 2026-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F15 · derivative.exercise_date: Option granted February 05, 2016 and vested monthly over four years.

SEC source: 0001209191-21-009115 · doc4.xml · nonDerivative · entry 10

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,361

F9 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F11 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.35 to $117.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-21-009115 · doc4.xml · nonDerivative · entry 9

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,369

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-009115 · doc4.xml · nonDerivative · entry 8

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,361

F9 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

SEC source: 0001209191-21-009115 · doc4.xml · nonDerivative · entry 7

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,547

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-009115 · doc4.xml · nonDerivative · entry 6

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,361

F9 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F10 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.31 to $117.22. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-21-009115 · doc4.xml · nonDerivative · entry 5

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,361

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-009134 · doc4.xml · derivative · entry 7

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,439

Underlying: Common Stock · 7,439 shares

Expires not disclosed

F12 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F13 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025.

F13 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025.

SEC source: 0001209191-21-009134 · doc4.xml · derivative · entry 6

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,632

Underlying: Common Stock · 44,632 shares

Expires 2031-02-08

F11 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

SEC source: 0001209191-21-009134 · doc4.xml · nonDerivative · entry 5

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,768

F9 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F10 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-21-009134 · doc4.xml · nonDerivative · entry 4

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,306

F7 · kind: Sale of 1,000 shares of common stock issued upon vesting of 1,900 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (900) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-21-009134 · doc4.xml · nonDerivative · entry 3

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,406

F5 · kind: Sale of 1,070 shares of common stock issued upon vesting of 3,037 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,967) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above.

F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.06 to $117.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.